Browsing by Author Cunningham, David

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 11 of 11
Issue DateTitleAuthor(s)Citation
2012Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trialClarke, Stephen; Cartwright, Thomas; Cunningham, David; De Gramont, A.; et al, Various; Hecht, J; Im, Seock-Ah; Moore, Malcolm; Rivera, Fernando; Schmoll, Hans-Joachim; Tabernero, Josep; Van Cutsem, E; Concord Clinical School: MedicineBevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial, Lancet Oncology, vol.13, 12, 2012,pp 1225-1233
2010Capecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study.Gebski, Val; Simes, Robert John; Stockler, Martin; Zannino, Diana; Ackland, Stephen P.; Broad, Adam; Chua, Yu Jo; Cummins, Michelle; Cunningham, David; Forgeson, Garry; Ganju, Vinod; Price, Timothy; Robinson, Bridget; Saunders, M; Tebbutt, Niall C; van Hazel, Guy; Wilson, Kate; Zalcberg, J; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreCapecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study., Journal of Clinical Oncology (Online), vol.28, 19,pp 3191-3198
2015Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancerGebski, Val; Lee, Chee Khoon; Mann, Kristy; Simes, Robert John; Wilson, Kate; Bruhn, M; Cunningham, David; Hardingham, Jennifer; Price, Timothy; Robinson, B; Tebbutt, Niall; Townsend, Amanda; van Hazel, Guy; Weickhardt, Andrew; Wrin, Joseph; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreCorrelation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer, British Journal of Cancer, vol.112, 6, 2015,pp 963-970
2013Current opinion on optimal treatment for colorectal cancerPavlakis, Nick; Ackland, Stephen P.; Burge, Matthew; Cunningham, David; Haller, Daniel; Karapetis, Christos; Price, Timothy; Segelov, Eva; Shapiro, Jeremy; Sobrero, Alberto; Tebbutt, Niall C; Northern Clinical School: MedicineCurrent opinion on optimal treatment for colorectal cancer, Expert Review of Anticancer Therapy, vol.13, 5, 2013,pp 597-611
2016Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trialClarke, Stephen; Cunningham, David; et al, Various; Kim, Sunyoung; Kim, Tae; Kim, Taeyou; Park, Youngsuk; Roh, Jae; Schmoll, Hans-Joachim; Sclafani, Francesco; Tabernero, Josep; Northern Clinical School: Kolling InstituteDalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial, International Journal of Cancer, vol.140, 2, 2016,pp 431-439
2016Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trialClarke, Stephen; Cunningham, David; et al, Various; Kim, Sunyoung; Kim, Tae; Kim, Taeyou; Park, Youngsuk; Roh, Jae; Schmoll, Hans-Joachim; Sclafani, Francesco; Tabernero, Josep; Northern Clinical School: Kolling InstituteDalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial, International Journal of Cancer, vol.140, 2, 2016,pp 431-439
2008Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy in Advanced Lymphoma: A Phase II StudyFoo, Kerwyn; Cunningham, David; Horwich, A.; Johnson, Bernadette; Murthy, Vedang; Norman, Andrew; Thomas, Karen; Central Clinical School: MedicineEfficacy of Palliative Low-Dose Involved-Field Radiation Therapy in Advanced Lymphoma: A Phase II Study, Clinical Lymphoma, Myeloma & Leukemia, vol.8, 4, 2008,pp 241-245
2002Efficacy, tolerability and management of raltitrexed (Tomudex TM) monotherapy in patients with advanced colorectal cancer: a review of phase II/III trialsClarke, Stephen; Cunningham, David; Facchini, T.; Gonzalez Baron, M.; James, R.; Maroun, J.; Maughan, T. S.; Schulz, J.; Vincent, M.; Zalcberg, John; Concord Clinical School: ANZAC Research InstituteEfficacy, tolerability and management of raltitrexed (Tomudex TM) monotherapy in patients with advanced colorectal cancer: a review of phase II/III trials, European Journal Of Cancer, vol.38,(4),2002,pp 478-486
2009Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients-analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBOClarke, Stephen; Dent, Owen; Robertson, Graham; Cunningham, David; Sharma, Rohini; Smith, Paul; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: Surgery; Concord Clinical School: ANZAC Research InstituteInflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients-analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO, BMC Cancer, vol.9, N/A,pp 153-1-153-10
2008Potential regional differences for the tolerability profiles of fluoropyrimidinesClarke, Stephen; Allegra, C; Cassidy, J; Cunningham, David; et al, not known; Haller, D M; Hoff, P; Rothenberg, M; Saltz, Leonard B.; Concord Clinical School: ANZAC Research InstitutePotential regional differences for the tolerability profiles of fluoropyrimidines, Journal of Clinical Oncology, vol.26,(13),2008,pp 2118-2123
2014Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancerLee, Chee Khoon; Arentz, Georgia; Bruhn, Maressa; Cunningham, David; Hardingham, Jennifer; Hocking, Christopher; Price, Timothy; Shivasami, Aravind; Tebbutt, Niall C; Townsend, Amanda; Wrin, Joseph; School of Public Health: NH&MRC Clinical Trials CentreProangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer, International Journal of Cancer, vol.135, 3, 2014,pp 731-741